ABUS · Arbutus Biopharma Corp
$4.42
+0.01 (+0.23%)
At close · Jul 28
Market Cap
$871.14M
Shares
197.54M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.41
Open$4.41
Day$4.40–4.53
52W$3.20–5.38
Avg vol 30d2.6M
Short int19.7M · 9.9% float · 7.4d
Short vol68%
Last earningsNov 6, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 13
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−1%
below
Price vs 50-day avg
−2%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
56%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+7%
trailing
YTD return
−8%
this year
Relative strength
0%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
21 of 169 funds reported for Jun 30 · net +3.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.95% of float · ▲ +14.9% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+128%
Y/Y
EPS growth
+55%
Y/Y
Free cash flow
$-39.6M
Valuation
P/E 5.3
below peers
Balance sheet
$18.0M
net cash
Quant / Vol
risk profile
Volatility
47%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
4.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−1%
Neutral
Price vs 50-day avg
−2%
Neutral
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
56%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $5 › 200d $4 — 50d above 200d
Institutional flow
Accumulating
21 of 169 funds reported for Jun 30 · net +3.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
9.95% of float · ▲ +14.9% MoM · 7.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
169 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $3
Now $4 · 56%
52-wk high $5
vs 200-day avg -1%
vs 50-day avg -2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients that have achieved functional cure during Phase 2a clinical trials and long-term follow | 10 | As of December 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ABUS
this stock
Arbutus Biopharma Corp
|
$871.14M | -8.3% | +128.2% | 5.3 | 9.9% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.57B | +5.7% | +46.2% | 28.4 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.95B | -13.5% | +20.8% | 16.3 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +5.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ABUS | -3.3% | +0.0% | +6.8% | -8.1% | -8.3% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | -2.7% | -0.7% | 0.0% | -7.1% | -16.7% |